PEDIATRIC DRUG STUDY INCENTIVES UNDER REVISED KASSEBAUM BILL
Executive Summary
PEDIATRIC DRUG STUDY INCENTIVES UNDER REVISED KASSEBAUM BILL would be available to companies that study allergy and asthma drugs in children, as well as to those studying drugs that do not routinely bear pediatric indications. Revised from a version that was introduced at the end of the previous Congress, the bill (S 2010) introduced by Sen. Kassebaum (R-Kans.) April 12 removes the restrictions on the application of the incentives that were contained in the earlier draft. Kassebaum deleted the class exclusion for allergy and asthma drugs in response to suggestions that pediatric studies of such drugs are not sufficient.